Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma.

Yang, Eric H; Courtney, Cynthia; Garg, Vinisha; Fradley, Michael G; Schiller, Gary J

Yang, Eric H; Courtney, Cynthia; Garg, Vinisha; Fradley, Michael G; Schiller, Gary J.

Afiliação

Yang EH; 1UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine UCLA Cardiovascular Center, 100 Medical Plaza, Suite 630, Los Angeles, CA 90095 USA.
Courtney C; 2Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA USA.
Garg V; 1UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine UCLA Cardiovascular Center, 100 Medical Plaza, Suite 630, Los Angeles, CA 90095 USA.
Fradley MG; 3Cardio-oncology Program, Department of Cardiovascular Sciences, University of South Florida Morsani College of Medicine and H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL USA.
Schiller GJ; 2Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA USA.

Cardiooncology ; 4: 2, 2018.

Article em En | MEDLINE | ID: mdl-32154003

Palavras-chave

Cardiac biomarkers; Carfilzomib; Heart failure; Multiple myeloma; Proteasome inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Cardiooncology Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google